DE69434053D1 - Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität - Google Patents

Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität

Info

Publication number
DE69434053D1
DE69434053D1 DE69434053T DE69434053T DE69434053D1 DE 69434053 D1 DE69434053 D1 DE 69434053D1 DE 69434053 T DE69434053 T DE 69434053T DE 69434053 T DE69434053 T DE 69434053T DE 69434053 D1 DE69434053 D1 DE 69434053D1
Authority
DE
Germany
Prior art keywords
kgf
keratinocyte growth
growth factor
biological activity
increased biological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434053T
Other languages
English (en)
Other versions
DE122006000005I2 (de
DE122006000005I1 (de
DE69434053T2 (de
Inventor
J Gospodarowicz
Frank Masiarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69434053D1 publication Critical patent/DE69434053D1/de
Application granted granted Critical
Publication of DE69434053T2 publication Critical patent/DE69434053T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69434053T 1993-06-29 1994-04-28 Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität Expired - Lifetime DE69434053T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
US86427 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
DE69434053D1 true DE69434053D1 (de) 2005-01-20
DE69434053T2 DE69434053T2 (de) 2006-02-23

Family

ID=22198501

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69434053T Expired - Lifetime DE69434053T2 (de) 1993-06-29 1994-04-28 Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
DE1994634053 Active DE122006000005I2 (de) 1993-06-29 1994-04-28 Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1994634053 Active DE122006000005I2 (de) 1993-06-29 1994-04-28 Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t

Country Status (25)

Country Link
US (7) US5677278A (de)
EP (2) EP1493812A3 (de)
JP (4) JP3570516B2 (de)
KR (1) KR960703433A (de)
CN (1) CN1129955A (de)
AT (1) ATE278777T1 (de)
AU (1) AU681405B2 (de)
BG (1) BG100236A (de)
BR (1) BR9407035A (de)
CA (1) CA2166278A1 (de)
CZ (1) CZ343795A3 (de)
DE (2) DE69434053T2 (de)
DK (1) DK0706563T3 (de)
ES (1) ES2227527T3 (de)
FI (1) FI956203A (de)
FR (1) FR06C0004I2 (de)
HU (1) HUT73453A (de)
LU (1) LU91215I2 (de)
NL (1) NL300217I2 (de)
NO (1) NO955189D0 (de)
NZ (1) NZ266622A (de)
PL (1) PL312257A1 (de)
PT (1) PT706563E (de)
SK (1) SK153295A3 (de)
WO (1) WO1995001434A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (de) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (es) * 1994-10-13 2004-01-16 Amgen Inc. Metodo para purificar factores de crecimiento de queratinocitos.
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
CA2202075C (en) * 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
JP2001506975A (ja) * 1996-10-15 2001-05-29 アムジェン インコーポレイテッド ケラチノサイト増殖因子―２産物
EP1003770A4 (de) * 1997-06-19 2002-10-30 Inst Genetics Llc Sekretierte polypeptide sowie diese kodierende polynukleotide
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
US6485937B1 (en) 1999-10-15 2002-11-26 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
WO2002077155A2 (en) * 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Keratinocyte growth factor-2
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7265089B2 (en) 2001-08-21 2007-09-04 Chiron Corporation KGF polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
SI1827483T1 (sl) * 2004-12-15 2014-11-28 Swedish Orphan Biovitrum Ab (Publ) Terapevtske formulacije keratinocitnega rastnega faktorja
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
AU2022336409A1 (en) 2021-08-30 2024-02-15 Unichem Laboratories Limited Protein compositions for the treatment of inflammatory diseases
KR20230070596A (ko) * 2021-11-15 2023-05-23 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (de) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) * 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
CA2202390C (en) 1994-10-13 2005-05-17 Bao-Lu Chen Keratinocyte growth factor analogs
CA2202075C (en) 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using

Also Published As

Publication number Publication date
NZ266622A (en) 1997-10-24
US5843883A (en) 1998-12-01
CN1129955A (zh) 1996-08-28
JP3570516B2 (ja) 2004-09-29
WO1995001434A1 (en) 1995-01-12
JP2006075173A (ja) 2006-03-23
US6677301B1 (en) 2004-01-13
US5863767A (en) 1999-01-26
FR06C0004I2 (fr) 2006-12-29
JP2009062396A (ja) 2009-03-26
DK0706563T3 (da) 2005-01-31
ATE278777T1 (de) 2004-10-15
BG100236A (en) 1996-07-31
KR960703433A (ko) 1996-08-17
DE122006000005I2 (de) 2006-11-23
EP1493812A2 (de) 2005-01-05
FI956203A0 (fi) 1995-12-22
JP4662569B2 (ja) 2011-03-30
BR9407035A (pt) 1996-03-12
NL300217I2 (nl) 2006-05-01
JP2004166709A (ja) 2004-06-17
CZ343795A3 (en) 1996-07-17
US20090093400A1 (en) 2009-04-09
ES2227527T3 (es) 2005-04-01
NO955189L (no) 1995-12-20
FI956203A (fi) 1996-02-07
JPH09500267A (ja) 1997-01-14
US5677278A (en) 1997-10-14
EP1493812A3 (de) 2006-02-08
EP0706563B1 (de) 2004-10-06
US5773586A (en) 1998-06-30
HUT73453A (en) 1996-08-28
PL312257A1 (en) 1996-04-01
NO955189D0 (no) 1995-12-20
CA2166278A1 (en) 1995-01-12
AU681405B2 (en) 1997-08-28
PT706563E (pt) 2005-01-31
EP0706563A1 (de) 1996-04-17
FR06C0004I1 (de) 2006-03-10
DE122006000005I1 (de) 2006-08-10
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
US6074848A (en) 2000-06-13
LU91215I2 (en) 2006-03-27
DE69434053T2 (de) 2006-02-23
SK153295A3 (en) 1996-11-06
HU9503857D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
DE69434053D1 (de) Verkürzter keratinocyten-wachstumsfaktor(kgf)mit erhöhter biologischer aktivität
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE354659T1 (de) Polypeptide mit kinaseaktivität, ihre herstellung und verwendung
DE69024862D1 (de) Modifiziertes, biologisch aktives Protein
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
DE69126049D1 (de) Vektoren und Zusammensetzungen zur Expression von Glykosilationsmutanten des menschlichen Proteins-C
DE69225597T2 (de) Peptide mit einer lanthionin-brücke
AU3095892A (en) Human type antibody reactive with GPIIb/IIIa
DE59409964D1 (de) Rekombinante D-Hydantoinase, Verfahren zur Herstellung und Verwendung
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
CA2067176A1 (en) Recombinant gene coding for a protein having an endochitinase activity
IT1231764B (it) Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione.
EP0206329A3 (en) Sprung floor
AU4064293A (en) Textile material
EP0749981A4 (de) Monoklonaler antikörper
IT9021117V0 (it) Leva di comando particolarmente per l'azionamento di gruppi valvolari
MX9604896A (es) Mejoramientos en o relacionados a la resistencia de las plantas contra enfermedades.